Table 1.
Comparison of data between sacubitril valsartan group and valsartan group.
| Characteristic | Salkubatroxartan group (84) | Valsartan group (86) | t or χ2 | P |
| Age (yr), mean ± SD | 62.29 ± 12.82 | 63.49 ± 11.61 | −0.642 | .522 |
| Gender (male), n (%) | 52 (61.90%) | 56 (65.12%) | 0.664 | .750 |
| Hypertension, n (%) | 56 (66.67%) | 52 (60.47%) | 0.705 | .429 |
| SP (mm Hg) mean ± SD | 124.90 ± 18.68 | 128.91 ± 16.52 | −1.481 | .141 |
| Severity of myocardial infarction, n (%) | ||||
| Single vessel lesion | 7 (8.33%) | 11 (12.79%) | 0.892 | .456 |
| Double vessel lesion | 20 (23.81%) | 19 (22.62%) | 0.071 | .856 |
| Three vessel lesion | 56 (66.67%) | 56 (65.12%) | 0.045 | .872 |
| HbA1c (%), mean ± SD | 8.40 ± 1.67 | 8.05 ± 1.22 | 1.567 | .119 |
| FBG (mmol/L), mean ± SD | 10.41 ± 3.69 | 9.91 ± 3.54 | 0.902 | .368 |
| NT-proBNP (ng/L), mean ± SD | 679.10 ± 623.32 | 666.14 ± 407.78 | 0.161 | .872 |
| SCr (umol/L), mean ± SD | 69.69 ± 21.52 | 75.05 ± 25.77 | −1.468 | .144 |
| LDL-C (mmol/L), mean ± SD | 2.43 ± 0.83 | 2.54 ± 0.79 | −0.825 | .410 |
| Killip classification, n (%) | ||||
| I | 22 (26.19%) | 24 (27.91%) | 0.801 | .864 |
| II | 26 (30.95%) | 26 (30.23%) | 0.919 | 1.000 |
| III | 14 (16.67%) | 16 (18.60%) | 0.740 | .841 |
| IV | 22 (26.19%) | 20 (23.26%) | 0.657 | .723 |
| Drug use during treatment, n (%) | ||||
| β-blocker | 76 (90.48%) | 74 (86.05%) | 0.370 | .477 |
| Spironolactone | 26 (30.95%) | 30 (34.88%) | 0.586 | .627 |
| Digitalis | 32 (38.10%) | 30 (34.88%) | 0.664 | .750 |
| Diuretic | 2 (2.38%) | 2 (2.33%) | 0.981 | 1.000 |
| LVEF (%), mean ± SD | 44.69 ± 4.60 | 44.65 ± 4.42 | 0.057 | .955 |
| LVDD (mm), mean ± SD | 51.52 ± 6.20 | 50.05 ± 5.62 | 1.552 | .123 |
FBG = fasting blood glucose, HbA1c = hemoglobin A1c, LDL-C = low density lipoprotein-cholestero, LVDD = left ventricular end diastolic dimension, LVEF = left ventricular ejection fraction, NT-proBNP = N-terminal pro-brain natriuretic peptide, SCr = serum creatinine, SP = systolic pressure.